FDA Class II Recall: Imprimis NJOF's Epinephrine Lidocaine HCL Found Sub-Potent, Impacting US Supply Chains
Imprimis NJOF, LLC initiated a Class II recall for 6,880 vials of Epinephrine Lidocaine HCL due to sub-potency identified during stability testing. This nationwide US recall (D-0535-2025) highlights critical quality control failures, posing efficacy risks for patients. Procurement and regulatory teams must immediately assess their supply chain exposure and reinforce supplier qualification processes to mitigate similar product quality risks.
Critical Recall of Epinephrine Lidocaine HCL by Imprimis NJOF: Sub-Potency Risks Identified
Imprimis NJOF, LLC has initiated a voluntary Class II recall, designated D-0535-2025, for 6,880 vials of Epinephrine Lidocaine HCL, specifically the 0.25mg/mL and 7.5 mg/mL formulation packaged as 20x1 mL vials per carton. This action, initiated on July 9, 2025, and completed by July 30, 2025, stems from critical sub-potent assay results observed during routine stability testing. The affected product bears NDC: 71384-641-01 and originates from Lot: 24DEC017, with an expiration date of July 12, 2025. For procurement directors, this means an immediate and urgent need to verify existing inventories and quarantine any affected stock. A sub-potent drug, particularly one containing Epinephrine, a critical component often used in emergency settings, presents significant efficacy risks. Patients receiving a sub-potent dose may not achieve the intended therapeutic effect, potentially leading to adverse health consequences or treatment failures. Regulatory affairs heads must ensure their organizations have robust procedures for identifying and managing recalled products, including communication protocols with healthcare providers and downstream distributors. The failure in stability testing points to potential deficiencies in Imprimis NJOF, LLC's quality control systems, necessitating a thorough review of all products sourced from this manufacturer, even those not directly implicated in this specific recall. Business development executives should consider the reputational impact on Imprimis NJOF, LLC and how this event might influence future contracting and partnership opportunities within the pharmaceutical sector.
Operational Impact and Distribution Scope for Imprimis NJOF, LLC
The recall of Epinephrine Lidocaine HCL by Imprimis NJOF, LLC impacts the entire United States, as the distribution pattern for the affected lot (24DEC017) was nationwide. Operating from Ledgewood, NJ, United States, Imprimis NJOF, LLC initiated this voluntary recall, indicating their proactive engagement with the FDA following the discovery of the sub-potency issue. For supply chain VPs, this nationwide distribution underscores the complexity of managing pharmaceutical product recalls, requiring efficient reverse logistics and thorough reconciliation across all points of distribution. The Class II classification signifies that the use of or exposure to the sub-potent product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This classification, while not the most severe, still demands a swift and comprehensive response from all entities within the supply chain. Businesses procuring from Imprimis NJOF, LLC must now assess the potential for supply disruptions for this specific formulation of Epinephrine Lidocaine HCL and other related products. The firm's ability to quickly address and remediate the underlying quality control issues will be crucial for maintaining market confidence and ensuring continuity of supply for other essential medications they produce. This event serves as a critical reminder for all stakeholders to maintain rigorous oversight of their supplier's quality systems and recall readiness.
Implications for Pharmaceutical Procurement and Supply Chain Resilience
This sub-potent drug recall by Imprimis NJOF, LLC highlights fundamental vulnerabilities that procurement directors and supply chain VPs must address proactively. The failure during stability testing for Epinephrine Lidocaine HCL underscores the imperative for robust supplier qualification processes that extend beyond initial audits to continuous monitoring of quality control and manufacturing practices. Organizations relying on single-source suppliers for critical care medications like Epinephrine Lidocaine HCL face heightened risks of supply chain disruption and patient safety concerns when such quality issues arise. It is essential for procurement teams to diversify their supplier base, identifying and qualifying alternative manufacturers for key active pharmaceutical ingredients (APIs) and finished drug products. While specific alternative suppliers for Epinephrine Lidocaine HCL are not detailed in the available intelligence, the strategic imperative remains: reduce dependency and build resilience. Regulatory affairs heads should review their internal procedures for managing product quality complaints and non-conformances, ensuring that any issues identified with incoming materials or finished products are promptly investigated and reported. This incident reinforces the need for comprehensive risk management frameworks that include contingency planning for recalls, potential product shortages, and the associated commercial and reputational damage. Proactive engagement with suppliers to understand their quality systems, including stability testing protocols and data, is no longer merely good practice but a critical business requirement.
Navigating Future Regulatory Scrutiny and Market Dynamics
The completion of the D-0535-2025 recall for Epinephrine Lidocaine HCL by Imprimis NJOF, LLC on July 30, 2025, marks the end of the immediate corrective action. However, for regulatory affairs heads and business development executives, this event signals potential for increased FDA scrutiny on Imprimis NJOF, LLC's overall manufacturing and quality control operations. While the recall was voluntary and firm-initiated, the underlying cause—sub-potency due to stability testing failures—often triggers enhanced oversight, including potential future inspections or requests for detailed corrective and preventive action (CAPA) plans. Companies sourcing from Imprimis NJOF, LLC should conduct their own due diligence, assessing the firm’s response to this recall and its broader commitment to quality. The broader regulatory landscape, as evidenced by recent parallel events such as Essential Wellness Pharma's progesterone injection failing sterility assurance or FDA hearings impacting Amgen's market future, indicates a persistent focus on drug quality and compliance. This environment necessitates that all pharmaceutical manufacturers, and their partners, maintain impeccable quality systems. Business development teams should evaluate the long-term viability and regulatory risk profile of Imprimis NJOF, LLC as a supplier, considering how this recall might influence future contract negotiations or market positioning. Proactive communication and transparency from Imprimis NJOF, LLC regarding their remediation efforts will be vital for rebuilding trust and mitigating commercial impacts.